The Trademark Trial and Appeal Board (TTAB) ruled in favor of Finnegan client Combe Inc. in another case involving the company’s VAGISIL trademark. The panel held that Marke Enterprises cannot register “VAGISERT” for its feminine care products, as they are “legally identical” to Combe’s VAGISIL line of feminine care products and therefore would cause confusion in the marketplace. Marke Enterprises argued that “vagi-“ is a generic prefix referring to an anatomic structure, but Combe argued the prefix is not typically used to identify any particular type of product or body part. The TTAB agreed with Combe, citing Combe’s reputation in the market and stating that consumers aren’t conditioned to distinguish between VAGISIL, VAGISTAT, and VAGISERT based on "minute differences."
Read “Vagisil Maker Gets Rival's 'Vagisert' TM Blocked at TTAB”
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.